Citigroup’s Erasca ERAS Stock Holding History

Citigroup’s Portfolio ERAS Stock Details ERAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$733K	Buy	+40,000	New	+$572K	﹤0.01%	3671

Other funds holding ERAS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Citigroup's ERAS Position: Q2 2026 in Review

Citigroup increased its Erasca (ERAS) stake by 1,353% in Q2 2026, buying an estimated $9.5M and bringing the position to 713,534 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1419.

Citigroup first reported a position in ERAS in Q3 2021 and has held it in 20 quarters since. 256 funds tracked by Wall St. Rank hold ERAS as of Q2 2026.

Citigroup held 713,534 shares of Erasca worth $13.1M as of Q2 2026.
Citigroup bought 664,424 Erasca shares in Q2 2026, an estimated $9.5M.
Erasca made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1419 holding.
Citigroup first reported a position in Erasca in Q3 2021 and has held it in 20 quarters since.
256 funds tracked by Wall St. Rank held Erasca as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.